INTRODUCTION
============

It is estimated that there are 16 million cases of fractures in the United States every year. Despite most bone having excellent regenerative ability during fracture healing, approximately 5% to 10% of fractures have complications, such as delayed healing or nonunion [@b1-cln_74p1]-[@b3-cln_74p1]. Delayed healing and nonunion are defined as fractures that have not healed for 6 and 9 months, respectively [@b4-cln_74p1],[@b5-cln_74p1]. The complications result in extended treatment time, reduced quality of living and potential additional remedial surgery, which give the patients a heavy burden and have serious societal implications [@b1-cln_74p1],[@b6-cln_74p1]. Fracture repair is an intricate process regulated by numerous genes and is affected by chemokines, cytokines, growth factors and other molecules [@b7-cln_74p1]-[@b9-cln_74p1]. To promote bone regeneration and prevent complications, an in-depth understanding of the fracture healing process and the adoption of suitable interventions are essential.

Parathyroid hormone (PTH) plays a vital role in bone regeneration by stimulating the differentiation and proliferation of osteoblasts and osteoclasts [@b10-cln_74p1],[@b11-cln_74p1]. Osteoporosis has been treated with intact PTH (1-84) and teriparatide, which is an N-terminal fragment (1-34) of PTH [@b12-cln_74p1]. Currently, teriparatide is the only anabolic bone therapeutic medicine to treat osteoporosis approved by the Food and Drug Administration (FDA) [@b13-cln_74p1]-[@b16-cln_74p1]. In patients with high fracture risk, PTH can improve bone quality and prevent fractures [@b17-cln_74p1].

As described previously, PTH treatment could increase bone formation biomarkers higher than it increases bone resorption biomarkers [@b18-cln_74p1],[@b19-cln_74p1]. Some animal studies have demonstrated that daily application of PTH (1-34) could increase bone mineral density to accelerate fracture healing and persistently affect the remodeling callus during fracture healing [@b20-cln_74p1],[@b21-cln_74p1]. Furthermore, studies have shown that PTH could improve fracture healing at different skeletal sites of patients [@b22-cln_74p1]-[@b24-cln_74p1]. However, we found that recent studies in the literature were inconsistent regarding the effects of PTH treatment on fracture healing [@b25-cln_74p1],[@b26-cln_74p1].

Therefore, a meta-analysis on randomized controlled trials (RCTs) was performed to demonstrate whether PTH can promote fracture healing by comparing PTH treatment to a placebo treatment or no treatment in patients with fracture.

METHODS
=======

This meta-analysis was conducted based on the Cochrane Handbook for Systematic Reviews of Interventions [@b27-cln_74p1] and presented in compliance with Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines (PRISMA) [@b28-cln_74p1].

Search strategy
---------------

The EMBASE, PubMed, and Cochrane Library databases were systematically searched from the inception dates to April 26, 2018. The keywords and Medical Subject Headings (MeSH) were "Parathyroid Hormone", "Hormone, Parathyroid", "Parathormone", "Parathyrin", "Parathyroid Hormone Peptide (1-34)", "PTH (1-34)", "Parathyroid Hormone (1-34)", "Teriparatide", "hPTH (1-34)", "Human Parathyroid Hormone (1-34)", "Parathar", "Teriparatide Acetate", "Forteo", "Parathyroid Hormone (1-84)" and "PTH (1-84)" in combination with "Fracture Healing", "Healing, Fracture", "Healings, Fracture" and "Fracture Healings". We did not restrict the language. The detailed search strategy is reported in the supplement. We identified original RCTs and did not obtain additional information by contacting authors of the primary studies.

Inclusion criteria
------------------

Studies were included if they met the following criteria: (A) participants, aged 21 to 94 years old, were patients with fractures and treated by PTH; (B) RCTs comparing the PTH intervention with a placebo or no treatment; (C) teriparatide was subcutaneously injected at 20 μg per day, or PTH (1-84) was administered at 100 μg per day; and (D) trials provided the relevant data.

Studies were excluded if they met the following criteria: (A) the patients had been using PTH, unless they had experienced a wash-out period; (B) there were contraindications to related drugs at any time; (C) any other antiosteoporotic drug had been taken in either the experimental group or comparison group; (D) liver enzymes were more than twice the upper limit or serum calcium was higher than the reference level; (E) patients had rheumatoid arthritis, pathologic fractures, history of tumor or chemotherapy, metabolic bone disease, chronic renal failure, or any disease affecting bone metabolism; (F) the studies were published as abstracts, reviews or letters; or (G) the articles were not available or the data had already been published.

Risk-of-bias assessments
------------------------

According to the Cochrane risk-of-bias criteria [@b27-cln_74p1], 2 researchers (HH, YL) independently evaluated the methodological quality of the selected RCTs. Every quality item was classified into unclear risk, low risk, or high risk. Any disagreements about a trial were resolved through discussion or consultation with an expert. Seven items were used to assess bias, as shown in [Figure 2](#f2-cln_74p1){ref-type="fig"}. Other bias was defined as trials with dissimilar baseline characteristics between groups or with sponsorship coming from drug companies.

Data extraction
---------------

The following information from each study was extracted independently by two researchers (HH, TS): authors, publication year, participant characteristics, number of cases, type of fracture, duration of trials, explicit treatment, drug dose, fracture healing-related data and adverse events. Any disagreements were resolved through discussion. We only extracted the relevant information and data from the original articles when more than 2 groups were compared in the study.

The primary endpoints were the fracture healing rate and time. When three of four fracture cortices were connected by the bone bridge shown on either lateral or anteroposterior radiographs, the fracture was considered healed [@b29-cln_74p1]-[@b35-cln_74p1]. A visual analog scale (VAS) [@b31-cln_74p1],[@b34-cln_74p1],[@b36-cln_74p1],[@b37-cln_74p1] and the Patient-Rated Wrist Evaluation (PRWE) were common methods for estimating degree of pain [@b33-cln_74p1]. Kinematic mobility could quantify functional outcomes using the PRWE [@b33-cln_74p1], "Disabilities of the Arm, Shoulder, and Hand" scoring (DASH) [@b37-cln_74p1], Johanson Hip Rating Questionnaire (JHRQ) [@b30-cln_74p1], or Timed "Up and Go" test (TUG) [@b31-cln_74p1]. Because adverse events were reported by inconsistent methods [@b29-cln_74p1],[@b32-cln_74p1],[@b33-cln_74p1],[@b36-cln_74p1],[@b37-cln_74p1], we could not pool the relevant data and only describe them in [Table 7](#t7-cln_74p1){ref-type="table"}.

Statistical analysis
--------------------

Our meta-analysis was conducted in Revman version 5.3 from the Cochrane Collaboration. We calculated the odds ratio (OR) and 95% confidence intervals (CIs) using the Mantel-Haenszel statistical method for dichotomous outcomes, while we determined mean difference (MD) or standard mean difference (SMD) and 95% CIs using the inverse variance statistical method for continuous outcomes. The analyses were 2-tailed, and the data pooled with a random-effects model. *p*\<0.05 was considered statistically significant. Statistical heterogeneity in the summary data was assessed with I^2^ statistics and *p*-values (I^2^\>50% or *p*-value\<0.10 was considered to indicate significant heterogeneity) [@b38-cln_74p1],[@b39-cln_74p1]. Sensitivity analyses were fulfilled by excluding the trials one by one. We performed subgroup analyses to appraise whether clinical characteristics could alter the results, to evaluate the statistical significance between the subgroups, and to estimate the publication bias with funnel plots.

Grading of evidence quality
---------------------------

Regarding risk of bias, inconsistency, indirectness, imprecision, and publication bias, the quality of evidence was independently assessed by two authors (HH, YL) based on the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) [@b40-cln_74p1] methodology. The estimated results were classified as very low, low, moderate, or high. We constructed a summary table using the GRADE Profiler (version 3.6).

RESULTS
=======

Literature search and characteristics
-------------------------------------

From the recently published studies, 121 potentially eligible RCTs were screened by titles and abstracts. There were 26 records read in full. Eventually, 8 records were in conformity with the inclusion criteria. A manual search of the reference lists within these studies did not reveal additional eligible studies. The process of screening the studies is illustrated in [Figure 1](#f1-cln_74p1){ref-type="fig"}.

Ultimately, in the meta-analysis, there were 524 participants from 8 RCTs, of which 79.6% were women and 20.4% were men. The mean age was 73.0 years old. For the fracture type, two trials had upper limb fractures (including distal radial fractures and proximal humeral fractures), five trials had lower limb fractures (including lower-extremity stress fracture, femoral neck fracture, trochanteric fractured neck of femur, osteoporotic intertrochanteric fractures, and hip fractures), and one trial had pelvic fracture. The general characteristics of the included studies are presented in [Table 1](#t1-cln_74p1){ref-type="table"}.

The experimental groups received once-daily subcutaneous treatment with 20 μg of teriparatide or 100 μg of PTH (1-84). The anabolic effect of 20 μg teriparatide is equivalent to 100 μg PTH (1-84) because of the differences in pharmacokinetics (41). The control group received a placebo, no treatment, or other drugs. The duration of PTH treatment ranged from 4 weeks to 24 months. The study by Aspenberg et al. (33) included two experimental groups, taking 20 μg or 40 μg teriparatide. In the study by Huang et al. (34), the two experimental groups could take either 20 μg teriparatide or 20 μg teriparatide plus 70 mg alendronate. Additionally, the study by Kanakaris et al. (30) had two control groups that took either vitamin D and calcium or vitamin D and calcium plus 70 mg alendronate. We excluded those ineligible groups. The detailed characteristics are shown in [Table 2](#t2-cln_74p1){ref-type="table"}.

Risk-of-bias assessments
------------------------

Methodological quality is shown in [Figure 2](#f2-cln_74p1){ref-type="fig"}. The incidence of the follow-up loss in patients was appraised, but only three trials had reported follow-up rates, which were all lower than 20%.

Radiographic assessment of fracture healing
-------------------------------------------

Three trials (251 patients) compared PTH treatment with either a placebo or no treatment for the time until radiological fracture healing [@b31-cln_74p1],[@b33-cln_74p1],[@b34-cln_74p1]. The MD method was adopted. As shown in [Figure 3](#f3-cln_74p1){ref-type="fig"}, there was a statistically significant difference in fracture healing time (MD -3.05, 95% CI -5.96 to -0.14, *p*=0.04; I^2^ of heterogeneity 97%, *p*-value of heterogeneity \<0.00001). A sensitivity analysis showed that the heterogeneity was significantly lower after the trial by Peichl et al. [@b31-cln_74p1] was excluded ([Table 3](#t3-cln_74p1){ref-type="table"}).

Four trials (256 patients) compared PTH treatment with either a placebo or no treatment regarding the rate of radiological fracture healing [@b29-cln_74p1]-[@b32-cln_74p1]. The OR method was adopted. The results are shown in [Figure 4](#f4-cln_74p1){ref-type="fig"}. There was no statistically significant difference in the fracture healing rate (OR 7.84, 95% CI 0.47 to 130.27, *p*=0.15; I^2^ of heterogeneity 85%, *p*-value of heterogeneity =0.0002). In a sensitivity analysis, the heterogeneity was significantly lower after the trial by Peichl et al. [@b31-cln_74p1] was excluded ([Table 4](#t4-cln_74p1){ref-type="table"}).

Fracture pain degree
--------------------

Five trials (320 patients) compared PTH treatment with either a placebo or no treatment on the degree of fracture pain by VAS or PRWE scores [@b31-cln_74p1],[@b33-cln_74p1],[@b34-cln_74p1],[@b36-cln_74p1],[@b37-cln_74p1]. Pain and numbness were evaluated by VAS scores in patients with trauma [@b31-cln_74p1],[@b34-cln_74p1],[@b36-cln_74p1],[@b37-cln_74p1], while pain and function were evaluated by PRWE scores in patients with distal radius fractures [@b33-cln_74p1]. Due to the different scoring criteria, the SMD method was adopted. The results are shown in [Figure 5](#f5-cln_74p1){ref-type="fig"}. There was a statistically significant difference in fracture pain degree (SMD -1.42, 95% CI -2.55 to -0.29, *p*=0.01; I^2^ of heterogeneity 94%, *P* value of heterogeneity \<0.00001). Considering the significant heterogeneity, we did a subgroup analysis on the basis of the distinct scoring methods. In the VAS score subgroup, there was still significant heterogeneity (I^2^ of heterogeneity 94%, *p*-value of heterogeneity \<0.00001). We further performed a sensitivity analysis in the VAS score subgroup and found that the heterogeneity was significantly lower after the trial by Peichl et al. [@b31-cln_74p1] was excluded ([Table 5](#t5-cln_74p1){ref-type="table"}).

Functional outcome
------------------

Four trials (178 patients) compared PTH treatment with either a placebo or no treatment on functional outcomes [@b30-cln_74p1],[@b31-cln_74p1],[@b33-cln_74p1],[@b37-cln_74p1]. The functional outcome was assessed with the TUG test or the self-administered PRWE questionnaire, DASH score or JHRQ [@b30-cln_74p1],[@b31-cln_74p1],[@b33-cln_74p1],[@b37-cln_74p1]. Due to the different methods, the SMD method was appropriate. The results are shown in [Figure 6](#f6-cln_74p1){ref-type="fig"}. The patients with PTH treatment were significantly superior to those with a placebo or no treatment in functional outcome (SMD -1.28, 95% CI -2.33 to -0.24, *p*=0.02; I^2^ of heterogeneity 88%, *p*-value of heterogeneity \<0.00001). In view of the result that there was significant heterogeneity (I^2^=88%), we performed a subgroup analysis based on the duration of treatment. One group had the treatment time being equal to 4 weeks (SMD -0.42, 95% CI -0.97 to 0.13, *p*=0.13; I^2^ of heterogeneity 7%, *p* of heterogeneity =0.30) and the other group included the treatment time exceeding 4 weeks (SMD -2.17, 95% CI -2.89 to -1.45, *p*\<0.00001; I^2^ of heterogeneity 57%, *p* of heterogeneity =0.13). The sensitivity analysis for the functional outcomes showed that the heterogeneity was not significantly lower after any study was excluded ([Table 6](#t6-cln_74p1){ref-type="table"}). Importantly, in this meta-analysis, the functional outcomes were better when the treatment times were longer than 4 weeks.

Adverse events
--------------

The trial by Peichl et al. declared that no deaths or adverse events were recorded [@b31-cln_74p1]. The trial by Huang et al. and Kanakaris et al. did not mention the relevant statistics about adverse events [@b30-cln_74p1],[@b34-cln_74p1]. Five trials reported adverse events with inconsistent methods [@b29-cln_74p1],[@b32-cln_74p1],[@b33-cln_74p1],[@b36-cln_74p1],[@b37-cln_74p1]. Therefore, we could not pool the relevant data, but describe them in [Table 7](#t7-cln_74p1){ref-type="table"}. In comparing the PTH treatment group with a control group, there was no significant difference in light-headedness, hypercalcemia, nausea, sweating, and headache, except for slight bruising at the injection site.

Publication Bias and GRADE Profile Evidence
-------------------------------------------

For this meta-analysis, there was no evidence showing obvious publication bias by examining the symmetry of the funnel plots ([Figure 7](#f7-cln_74p1){ref-type="fig"}), but a funnel shape reference line could not be provided by the software due to the small number of studies. GRADE evidence profiles are shown in [Table 8](#t8-cln_74p1){ref-type="table"}. There were no blind methods in the trials by Huang et al. and Johansson et al., no random processing in the trial by Huang et al., and inconsistent results in the trial by Bhandari et al.; these studies contrasted with the other three trials. Clearly, the most common reasons for the decreased level of evidence were the possible risk of bias and inconsistency.

DISCUSSION
==========

In this meta-analysis, we summarized that PTH treatment in patients with fracture was better than a placebo or no treatment based on the time for fracture healing, the degree of fracture pain, and the functional outcomes ([Figure 8](#f8-cln_74p1){ref-type="fig"}). There is great clinical value in healing fractures over a shorter time, with reductions in pain and with functional improvements [@b42-cln_74p1]. Therefore, these results showed the effectiveness of PTH in fracture healing. However, previous studies were inconsistent with the effect of PTH on fracture healing [@b25-cln_74p1],[@b26-cln_74p1]. It was shown that PTH is effective in accelerating fracture healing in the study by Lou et al. [@b25-cln_74p1], but not in the study by Shi et al. [@b26-cln_74p1]. Their studies might have some limitations, such as including the patients who received other drugs or different doses [@b25-cln_74p1],[@b26-cln_74p1], only including the patients with osteoporosis [@b25-cln_74p1], or only including fracture healing time and functional change [@b25-cln_74p1]. Our study included a total of 524 patients with fractures from 8 RCTs involving recently published primary studies. We included more patients and relevant outcomes, and tried to exclude inappropriate patients.

However, heterogeneity was obvious in this meta-analysis, so sensitivity analyses and subgroup analyses were performed. We found that the heterogeneity was significantly lower by exclusion of the trial by Peichl et al. [@b31-cln_74p1]. Fractures at different sites can be healed by different mechanisms [@b43-cln_74p1]. One possible explanation of the heterogeneity was that limb fracture healing differed from pelvic fracture healing in response to the anabolic effect of PTH, and we need to study these two types of fractures separately. Another possible explanation is that the equivalence of teriparatide and PTH (1-84) for fracture healing is questionable. Similarly, comparing 4-week treatment [@b30-cln_74p1],[@b37-cln_74p1] with over 4-week treatment [@b31-cln_74p1],[@b33-cln_74p1] produced statistically significant differences in terms of functional improvement following fracture. Although PTH can improve early callus formation [@b44-cln_74p1], better effects may be observed with a longer duration of treatment. Therefore, a uniform duration of treatment is needed to support clinical decisions.

According to the results from the pooled data, PTH treatment accelerated fracture healing, which allows patients to return to normal life sooner and reduces the medical consumption and chronic morbidity associated with long-term treatment. Furthermore, PTH can be applied to any type of fracture, commenced at any time, and applied throughout the entire healing period. As a result, we suspect that PTH may be useful in the course of implant fixation and in the established nonunion fracture. Some studies have started to explore related issues [@b45-cln_74p1]-[@b50-cln_74p1], but the number of these studies is still limited, and most of them are small sample size. The hypotheses discussed here still need to be addressed by high-quality RCTs.

It was advantageous that our meta-analysis conformed to the recommendations of the Cochrane Collaboration [@b27-cln_74p1] and PRISMA guidelines [@b28-cln_74p1], and the quality of evidence for its outcomes was evaluated by GRADE system [@b40-cln_74p1]. However, there were still several limitations. First, there were only eight studies included, and the sample size was relatively small. Second, in our study, more than 79% of the fractures occurred in women, and the average age of participants was 73 years; therefore, we do not know whether the results are applicable to men or young adults. Third, it was difficult to guarantee consistent blindness because some RCTs lacked a placebo or were unclear about the "random sequence generation" and "allocation concealment".

In conclusion, we determined that the effectiveness and safety of PTH in fracture healing is reasonably well established and credible. At this time, there are not enough studies in this field, hence we must cautiously interpret these results, and more high-quality RCTs are needed to verify the differential effects of PTH on fracture healing in different populations.
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###### 

Characteristics of the included studies.

  Study ID                                   No. of patients   Age/years   Sex    Type of fracture         
  ------------------------------------------ ----------------- ----------- ------ ------------------ ----- ------------------------------------------
  Almirol et al., 2016 ([@b32-cln_74p1])     14                31.4        4.4    0                  14    Lower-extremity stress fracture
  Aspenberg et al., 2010 ([@b33-cln_74p1])   102               61.4        8.6    0                  102   Distal radius fracture
  Bhandari et al., 2016 ([@b29-cln_74p1])    159               70          10.5   42                 117   Femoral neck fracture
  Chesser et al., 2016 ([@b36-cln_74p1])     29                79.6        8.94   19                 10    Trochanteric fractured neck of femur
  Huang et al., 2016 ([@b34-cln_74p1])       189               81.2        8.5    61                 128   Osteoporotic intertrochanteric fractures
  Johansson et al., 2016 ([@b37-cln_74p1])   40                68          8.6    0                  40    Proximal humeral fracture
  Kanakaris et al., 2015 ([@b30-cln_74p1])   30                75          8.89   6                  24    Hip fractures (low energy)
  Peichl et al., 2011 ([@b31-cln_74p1])      65                82.8        4.1    0                  65    Pelvic fracture

SD, standard deviation.

###### 

Details of the interventions.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study ID                                   Intervention              No. of patients in every group   Treatment time           Time of initiation                          
  ------------------------------------------ ------------------------- -------------------------------- ------------------------ -------------------- ---------- ----------- ---------------
  Almirol et al., 2016 ([@b32-cln_74p1])     Teriparatide 20 μg/day\   \-                               Placebo\                 \-                   6/8        8 weeks     \<4 weeks
                                             calcium 1000 mg/day\                                       calcium 1000 mg/day\                                                 
                                             vitamin D 400 IU/day                                       vitamin D 400 IU/day                                                 

  Aspenberg et al., 2010 ([@b33-cln_74p1])   Teriparatide 20 μg/day    Teriparatide 40 μg/day           Placebo                  \-                   34/34/34   8 weeks     \<10 days

  Bhandari et al., 2016 ([@b29-cln_74p1])    Teriparatide 20 μg/day\   \-                               Placebo\                 \-                   78/81      6 months    \<14 day
                                             calcium ≤ 1000 mg/day\                                     calcium ≤ 1000 mg/day\                                               
                                             vitamin D ≤4000 IU/day                                     vitamin D ≤4000 IU/day                                               

  Chesser et al., 2016 ([@b36-cln_74p1])     Teriparatide 20 μg/day\   \-                               No placebo\              \-                   15/14      42 days     10 days
                                             calcium\                                                   calcium\                                                             
                                             vitamin D                                                  vitamin D                                                            

  Huang et al., 2016 ([@b34-cln_74p1])       Teriparatide 20 μg/day\   Teriparatide 20 μg/day\          No placebo\              \-                   47/59/83   6 months    after surgery
                                             calcium 600 mg/day\       calcium 600 mg/day\              calcium 600 mg/day\                                                  
                                             vitamin D 800 IU/day      vitamin D 800 IU/day\            vitamin D 800 IU/day                                                 
                                                                       Alendronate                                                                                           

  Johansson et al., 2016 ([@b37-cln_74p1])   Teriparatide 20 μg/day    \-                               No therapy               \-                   20/20      4 weeks     \<10 days

  Kanakaris et al., 2015 ([@b30-cln_74p1])   Teriparatide 20 μg/day\   \-                               No placebo\              Alendronate 70 mg\   9/10/11    4 weeks     \-
                                             calcium\                                                   calcium\                 calcium\                                    
                                             vitamin D                                                  vitamin D                vitamin D                                   

  Peichl et al., 2011 ([@b31-cln_74p1])      PTH (1-84) 100 μg/day\    \-                               No placebo\              \-                   21/44      24 months   \<2 days
                                             calcium 1000 mg\                                           calcium 1000 mg\                                                     
                                             vitamin D 800 IU                                           vitamin D 800 IU                                                     
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Sensitivity analyses based on various exclusion criteria for fracture healing time.

  Excluded trial                             No. of trials   No. of patients   Experimental group   Control group   MD (95% CI)              *p*-value for MD   I^2^,%   *p-*value for heterogeneity
  ------------------------------------------ --------------- ----------------- -------------------- --------------- ------------------------ ------------------ -------- -----------------------------
  Aspenberg et al., 2010 ([@b33-cln_74p1])   2 (31,34)       195               68                   127             -3.73 \[-8.53, 1.07\]    0.13               99       \<0.00001
  Huang et al., 2016 ([@b34-cln_74p1])       2 (31,33)       121               50                   71              -3.95 \[-8.36, 0.46\]    0.08               97       \<0.00001
  Peichl et al., 2011 ([@b31-cln_74p1])      2 (33,34)       186               76                   110             -1.38 \[-1.82, -0.94\]   \<0.00001          0        0.48

MD, mean difference.

###### 

Sensitivity analyses based on various exclusion criteria for fracture healing rate.

  Excluded trial                             No. of trials   No. of patients   Experimental group   Control group   OR (95% CI)              *p*-value for OR   I^2^, %   *p*-value for heterogeneity
  ------------------------------------------ --------------- ----------------- -------------------- --------------- ------------------------ ------------------ --------- -----------------------------
  Almirol et al., 2016 ([@b32-cln_74p1])     3 (29-31)       243               108                  135             10.94 \[0.19, 639.47\]   0.25               90        \<0.0001
  Bhandari et al., 2016 ([@b29-cln_74p1])    3 (30-32)       97                36                   61              19.60 \[1.00, 385.14\]   0.05               68        0.04
  Kanakaris et al., 2015 ([@b30-cln_74p1])   3 (29,31,32)    237               105                  132             9.21 \[0.23, 366.63\]    0.24               89        \<0.0001
  Peichl et al., 2011 ([@b31-cln_74p1])      3 (29,30,32)    191               93                   98              1.14 \[0.56, 2.31\]      0.72               2         0.36

OR, odds ratio.

###### 

Sensitivity analyses based on various exclusion criteria for the subgroup of fracture pain degree by VAS scores.

  Excluded trial                             No. of trials   No. of patients   Experimental group   Control group   SMD (95% CI)             *p*-value for SMD   I^2^,%   *p*-value for heterogeneity
  ------------------------------------------ --------------- ----------------- -------------------- --------------- ------------------------ ------------------- -------- -----------------------------
  Chesser et al., 2016 ([@b36-cln_74p1])     3 (31,34,37)    234               87                   147             -1.40 \[-3.03, 0.22\]    0.09                96       \<0.00001
  Huang et al., 2016 ([@b34-cln_74p1])       3 (31,36,37)    133               55                   78              -1.35 \[-3.33, 0.63\]    0.18                96       \<0.00001
  Johansson et al., 2016 ([@b37-cln_74p1])   3 (31,34,36)    224               83                   141             -1.48 \[-3.16, 0.20\]    0.09                95       \<0.00001
  Peichl et al., 2011 ([@b31-cln_74p1])      3 (34,36,37)    198               81                   117             -0.49 \[-0.78, -0.20\]   0.001               0        0.51

SMD, standardized mean difference.

###### 

Sensitivity analyses based on various exclusion criteria for functional outcomes.

  Excluded trial                             No. of trials   No. of patients   Experimental group   Control group   SMD (95% CI)             *p*-value for SMD   I^2^,%   *p*-value for heterogeneity
  ------------------------------------------ --------------- ----------------- -------------------- --------------- ------------------------ ------------------- -------- -----------------------------
  Johansson et al., 2016 ([@b37-cln_74p1])   3 (30,31,33)    139               58                   81              -1.51 \[-2.81, -0.20\]   0.02                89       \<0.0001
  Kanakaris et al., 2015 ([@b30-cln_74p1])   3 (31,33,37)    159               68                   91              -1.66 \[-2.74, -0.59\]   0.002               88       0.0003
  Aspenberg et al., 2010 ([@b33-cln_74p1])   3 (30,31,37)    123               49                   74              -0.87 \[-1.89, 0.16\]    0.10                84       0.002
  Peichl et al., 2011 ([@b31-cln_74p1])      3 (30,33,37)    113               56                   57              -1.09 \[-2.55, 0.38\]    0.15                91       \<0.0001

SMD, standardized mean difference.

###### 

Adverse effects.

  Study ID                                                           Adverse event description                                                    No. of events in experimental group (%)   No. of events in control group (%)   *p*-value
  ------------------------------------------------------------------ ---------------------------------------------------------------------------- ----------------------------------------- ------------------------------------ -----------
  Almirol et al., 2016 ([@b32-cln_74p1])                             Slight bruising at the injection site                                        6 (100%)                                  0 (0%)                               0.010
  Pea-sized bump below the site of fracture                          1 (16.7%)                                                                    0 (0%)                                    0.410                                
  Light-headedness                                                   0 (0%)                                                                       1 (14.3%)                                 0.520                                
  Aspenberg et al., 2010 ([@b33-cln_74p1])                           Serious adverse events                                                       0 (0%)                                    3 (8.8%)                             0.046
  Hypercalcemia                                                      0 (0%)                                                                       1 (2.9%)                                  0.490                                
  Nausea                                                             3 (8.8%)                                                                     0 (0%)                                    0.279                                
  A new distal radius fracture                                       0 (0%)                                                                       1 (2.9%)                                  0.490                                
  Bhandari et al., 2016 ([@b29-cln_74p1])                            Patients with \> 1 adverse events                                            35 (45%)                                  40 (49%)                             0.634
  Patients with \> 1 adverse events possibly related to study drug   5 (6%)                                                                       5 (6%)                                    1.000                                
  Patients with \> 1 serious adverse events                          3 (4%)                                                                       7 (9%)                                    0.329                                
  Chesser et al., 2016 ([@b36-cln_74p1])                             None of the serious adverse effects were related to the study intervention   8 (53%)                                   7 (50%)                              0.860
  Huang et al., 2016 ([@b34-cln_74p1])                               Not mentioned                                                                \-                                        \-                                   \-
  Johansson et al., 2016 ([@b37-cln_74p1])                           Nausea                                                                       3 (15.8%)                                 0(0%)                                0.160
  Episodes of sweating                                               2 (10.5%)                                                                    0(0%)                                     0.260                                
  Slight headache                                                    1 (5.3%)                                                                     0(0%)                                     0.470                                
  Kanakaris et al., 2015 ([@b30-cln_74p1])                           Not mentioned                                                                \-                                        \-                                   \-
  Peichl et al., 2011 ([@b31-cln_74p1])                              No adverse events or deaths were recorded                                    \-                                        \-                                   \-

###### 

GRADE evidence profiles for the outcomes

  Outcomes                             No. of Participants (studies) Follow-up                                                             Quality of the evidence (GRADE)      Relative effect (95% CI)   Anticipated absolute effects   
  ------------------------------------ --------------------------------------------------------------------------------------------------- ------------------------------------ -------------------------- ------------------------------ --------------------------------------------------------------------------------------------------------------------------------------
  Radiological fracture healing time   251 (3 studies) ([@b31-cln_74p1],[@b33-cln_74p1],[@b34-cln_74p1])                                   ⊕⊕⊕⊝ MODERATE due to risk of bias                                                              The mean radiological fracture healing time in the intervention groups was 3.06 lower (6.12 lower to 0.01 higher)
  Radiological fracture healing rate   256 (4 studies) ([@b29-cln_74p1]-[@b32-cln_74p1])                                                   ⊕⊕⊕⊝ MODERATE due to inconsistency   OR 7.84 (0.47 to 130.27)   514 per 1000                   378 more per 1000 (from 182 fewer to 479 more)
  Fracture pain degree                 320 (5 studies) ([@b31-cln_74p1],[@b33-cln_74p1],[@b34-cln_74p1],[@b36-cln_74p1],[@b37-cln_74p1])   ⊕⊕⊕⊝ MODERATE due to risk of bias                                                              The mean fracture pain degree in the intervention groups was 1.42 standard deviations lower (2.55 to 0.29 lower)
  Fracture pain degree, PRWE scores    57 (1 study) ([@b33-cln_74p1])                                                                      ⊕⊕⊕⊕ HIGH                                                                                      The mean fracture pain degree, PRWE scores in the intervention groups, was 2.53 standard deviations lower (3.24 to 1.82 lower)
  Fracture pain degree, VAS scores     263 (4 studies) ([@b31-cln_74p1],[@b34-cln_74p1],[@b36-cln_74p1],[@b37-cln_74p1])                   ⊕⊕⊕⊝ MODERATE due to risk of bias                                                              The mean fracture pain degree, VAS scores in the intervention groups, was 1.15 standard deviations lower (2.36 lower to 0.07 higher)
  Functional outcome                   178 (4 studies) ([@b30-cln_74p1],[@b31-cln_74p1],[@b33-cln_74p1],[@b37-cln_74p1])                   ⊕⊕⊕⊝ MODERATE due to risk of bias                                                              The mean functional outcome in the intervention groups was 1.28 standard deviations lower (2.33 to 0.24 lower)
  Functional outcome, 4 weeks          58 (2 studies) ([@b30-cln_74p1],[@b37-cln_74p1])                                                    ⊕⊕⊕⊝ MODERATE due to risk of bias                                                              The mean functional outcome, 4 weeks in the intervention groups, was 0.42 standard deviations lower (0.97 lower to 0.13 higher)
  Functional outcome, over 4 weeks     120 (2 studies) ([@b31-cln_74p1],[@b33-cln_74p1])                                                   ⊕⊕⊕⊕ HIGH                                                                                      The mean functional outcome, over 4 weeks in the intervention groups, was 2.17 standard deviations lower (2.89 to 1.45 lower)

The basis for the assumed risk (e.g., the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: confidence interval; OR: odds ratio; GRADE: Working Group grades of evidence; High quality: Further research is very unlikely to change our confidence in the estimate of the effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of the effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of the effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate.
